South Korea Androgenetic Alopecia Market Size & Outlook
Global Market
Related Markets
South Korea androgenetic alopecia market highlights
- The South Korea androgenetic alopecia market generated a revenue of USD 90.4 million in 2023 and is expected to reach USD 172.7 million by 2030.
- The South Korea market is expected to grow at a CAGR of 9.7% from 2024 to 2030.
- In terms of segment, pharmaceuticals was the largest revenue generating treatment in 2023.
- Devices is the most lucrative treatment segment registering the fastest growth during the forecast period.
Androgenetic alopecia market data book summary
| Market revenue in 2023 | USD 90.4 million |
| Market revenue in 2030 | USD 172.7 million |
| Growth rate | 9.7% (CAGR from 2023 to 2030) |
| Largest segment | Pharmaceuticals |
| Fastest growing segment | Devices |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pharmaceuticals, Devices |
| Key market players worldwide | Johnson & Johnson, Cipla Ltd DR, Sun Pharmaceutical Industries, Merck & Co Inc, Dr. Reddy’s Laboratories, Cardiff Lexington Corp, Amgen Inc, Theradome, Aurobindo Pharma, Curallux, Apira Science |
Other key industry trends
- In terms of revenue, South Korea accounted for 3.3% of the global androgenetic alopecia market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China androgenetic alopecia market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 174.0 million by 2030.
A large population base in South Korea is suffering from alopecia, with an approximate 1.3:1 male-tofemale ratio. Market growth in the country is driven by technological advancements and new product developments. For instance, in October 2020, a South Korean company, LG Electronics, received approval for its laser therapy-based helmet for the treatment of AGA.
Local players focus on addressing unmet needs of patients. The Ministry of Food and Drug Safety (MFDS) approved the generic version of Avodart by JW Pharmaceutical, JW shinyak, Dong-A ST Co. Ltd, and Daehan New Pharm Co., Ltd. These companies are reformulating dosage forms to enhance patient compliance, as Avodart and previous generics were available in soft gelatin capsules.
Moreover, a team of scientists identified that CXXC5 protein downregulates the WNT signaling pathway, which controls hair regeneration and follicular development. In line with this, PTD-DMB is considered to be a potential biochemical agent to combat alopecia. These factors and initiatives are expected to drive market growth.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Androgenetic Alopecia Market Scope
Androgenetic Alopecia Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Cipla Ltd DR | View profile | 38,955 | Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, India, 400 013 | www.cipla.com |
| Aurobindo Pharma | View profile | 10001+ | Hyderabad, Andhra Pradesh, India, Asia | aurobindo.com |
| Sun Pharmaceutical Industries | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | www.sunpharma.com |
| Dr. Reddy’s Laboratories | View profile | 10001+ | Hyderabad, Andhra Pradesh, India, Asia | www.drreddys.com/ |
| Cardiff Lexington Corp | View profile | 13 | 3753 Howard Hughes Parkway, Suite 200, Las Vegas, NV, United States, 89169 | www.cardifflexington.com |
| Theradome | View profile | 1-10 | Pleasanton, California, United States, North America | www.theradome.com/ |
| Curallux | View profile | 101-250 | Miami, Florida, United States, North America | curallux.com/ |
South Korea Androgenetic Alopecia Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Androgenetic Alopecia Market Outlook will help companies and investors design strategic landscapes.
Pharmaceuticals was the largest segment with a revenue share of 98.56% in 2023.
Horizon Databook has segmented the South Korea androgenetic alopecia market based on pharmaceuticals, devices covering the revenue growth of each sub-segment from 2018 to 2030.
A large population base in South Korea is suffering from alopecia, with an approximate 1.3:1 male-tofemale ratio. Market growth in the country is driven by technological advancements and new product developments. For instance, in October 2020, a South Korean company, LG Electronics, received approval for its laser therapy-based helmet for the treatment of AGA.
Local players focus on addressing unmet needs of patients. The Ministry of Food and Drug Safety (MFDS) approved the generic version of Avodart by JW Pharmaceutical, JW shinyak, Dong-A ST Co. Ltd, and Daehan New Pharm Co., Ltd. These companies are reformulating dosage forms to enhance patient compliance, as Avodart and previous generics were available in soft gelatin capsules.
Moreover, a team of scientists identified that CXXC5 protein downregulates the WNT signaling pathway, which controls hair regeneration and follicular development. In line with this, PTD-DMB is considered to be a potential biochemical agent to combat alopecia. These factors and initiatives are expected to drive market growth.
- South Korea Androgenetic Alopecia Market Treatment Outlook (Revenue, USD MIllion , 2018-2030)
- Pharmaceuticals
- Devices
- South Korea Androgenetic Alopecia Market End-use Outlook (Revenue, USD MIllion , 2018-2030)
- Homecare Settings
- Dermatology Clinics
- South Korea Androgenetic Alopecia Market Sales Channel Outlook (Revenue, USD MIllion , 2018-2030)
- Prescriptions
- OTC
- South Korea Androgenetic Alopecia Market Gender Outlook (Revenue, USD MIllion , 2018-2030)
- Male
- Female
Reasons to subscribe to Androgenetic Alopecia Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Androgenetic Alopecia Market Outlook databook
- Our clientele includes a mix of Androgenetic Alopecia Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea Androgenetic Alopecia Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into South Korea Androgenetic Alopecia Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
South Korea Androgenetic Alopecia Market, 2018-2030 (US$M)
South Korea androgenetic alopecia market statistics, by treatment, 2018-2030 (US$M)
